Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

(-)-Oleocanthal and (-)-oleocanthal-rich olive oils induce lysosomal membrane permeabilization in cancer cells.

Goren L, Zhang G, Kaushik S, Breslin PAS, Du YN, Foster DA.

PLoS One. 2019 Aug 14;14(8):e0216024. doi: 10.1371/journal.pone.0216024. eCollection 2019.

2.

Glutamine as an Essential Amino Acid for KRas-Driven Cancer Cells.

Bernfeld E, Foster DA.

Trends Endocrinol Metab. 2019 Jun;30(6):357-368. doi: 10.1016/j.tem.2019.03.003. Epub 2019 Apr 27. Review.

PMID:
31040047
3.

Early Miocene CO2 estimates from a Neotropical fossil leaf assemblage exceed 400 ppm.

Londoño L, Royer DL, Jaramillo C, Escobar J, Foster DA, Cárdenas-Rozo AL, Wood A.

Am J Bot. 2018 Nov;105(11):1929-1937. doi: 10.1002/ajb2.1187. Epub 2018 Nov 12.

PMID:
30418663
4.

Phospholipase D-dependent mTOR complex 1 (mTORC1) activation by glutamine.

Bernfeld E, Menon D, Vaghela V, Zerin I, Faruque P, Frias MA, Foster DA.

J Biol Chem. 2018 Oct 19;293(42):16390-16401. doi: 10.1074/jbc.RA118.004972. Epub 2018 Sep 7.

PMID:
30194281
5.

Probing Position-Dependent Diffusion in Folding Reactions Using Single-Molecule Force Spectroscopy.

Foster DAN, Petrosyan R, Pyo AGT, Hoffmann A, Wang F, Woodside MT.

Biophys J. 2018 Apr 10;114(7):1657-1666. doi: 10.1016/j.bpj.2018.02.026.

6.

Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes.

Utter M, Chakraborty S, Goren L, Feuser L, Zhu YS, Foster DA.

Cancer Lett. 2018 Jun 1;423:28-35. doi: 10.1016/j.canlet.2018.03.006. Epub 2018 Mar 8.

7.

Lipid sensing by mTOR complexes via de novo synthesis of phosphatidic acid.

Menon D, Salloum D, Bernfeld E, Gorodetsky E, Akselrod A, Frias MA, Sudderth J, Chen PH, DeBerardinis R, Foster DA.

J Biol Chem. 2017 Apr 14;292(15):6303-6311. doi: 10.1074/jbc.M116.772988. Epub 2017 Feb 21.

8.

A Late G1 Lipid Checkpoint That Is Dysregulated in Clear Cell Renal Carcinoma Cells.

Patel D, Salloum D, Saqcena M, Chatterjee A, Mroz V, Ohh M, Foster DA.

J Biol Chem. 2017 Jan 20;292(3):936-944. doi: 10.1074/jbc.M116.757864. Epub 2016 Dec 12.

9.

Direct observation of transition paths during the folding of proteins and nucleic acids.

Neupane K, Foster DA, Dee DR, Yu H, Wang F, Woodside MT.

Science. 2016 Apr 8;352(6282):239-42. doi: 10.1126/science.aad0637.

10.

First North American fossil monkey and early Miocene tropical biotic interchange.

Bloch JI, Woodruff ED, Wood AR, Rincon AF, Harrington AR, Morgan GS, Foster DA, Montes C, Jaramillo CA, Jud NA, Jones DS, MacFadden BJ.

Nature. 2016 May 12;533(7602):243-6. doi: 10.1038/nature17415. Epub 2016 Apr 20.

PMID:
27096364
11.

Aspartate Rescues S-phase Arrest Caused by Suppression of Glutamine Utilization in KRas-driven Cancer Cells.

Patel D, Menon D, Bernfeld E, Mroz V, Kalan S, Loayza D, Foster DA.

J Biol Chem. 2016 Apr 22;291(17):9322-9. doi: 10.1074/jbc.M115.710145. Epub 2016 Feb 26.

12.

The Enigma of Rapamycin Dosage.

Mukhopadhyay S, Frias MA, Chatterjee A, Yellen P, Foster DA.

Mol Cancer Ther. 2016 Mar;15(3):347-53. doi: 10.1158/1535-7163.MCT-15-0720. Epub 2016 Feb 25. Review.

13.

Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation.

Mukhopadhyay S, Saqcena M, Foster DA.

Oncoscience. 2015 Sep 23;2(10):807-8. eCollection 2015. No abstract available.

14.
15.

5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells.

Mukhopadhyay S, Chatterjee A, Kogan D, Patel D, Foster DA.

Cell Cycle. 2015;14(20):3331-9. doi: 10.1080/15384101.2015.1087623.

16.

Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle.

Saqcena M, Patel D, Menon D, Mukhopadhyay S, Foster DA.

Cell Cycle. 2015;14(14):2285-92. doi: 10.1080/15384101.2015.1046653. Epub 2015 May 6.

17.

Rapamycin-induced G1 cell cycle arrest employs both TGF-β and Rb pathways.

Chatterjee A, Mukhopadhyay S, Tung K, Patel D, Foster DA.

Cancer Lett. 2015 May 1;360(2):134-40. doi: 10.1016/j.canlet.2015.01.043. Epub 2015 Feb 3.

18.

Reciprocal regulation of AMP-activated protein kinase and phospholipase D.

Mukhopadhyay S, Saqcena M, Chatterjee A, Garcia A, Frias MA, Foster DA.

J Biol Chem. 2015 Mar 13;290(11):6986-93. doi: 10.1074/jbc.M114.622571. Epub 2015 Jan 29.

19.

Reconstructing folding energy landscape profiles from nonequilibrium pulling curves with an inverse Weierstrass integral transform.

Engel MC, Ritchie DB, Foster DA, Beach KS, Woodside MT.

Phys Rev Lett. 2014 Dec 5;113(23):238104. Epub 2014 Dec 3.

PMID:
25526163
20.

In memoriam: Geoffrey Louis Zubay, 1931-2014. Pioneer in cell-free gene expression studies and molecular genetics.

Foster DA.

Trends Biochem Sci. 2014 Nov;39(11):505-6. doi: 10.1016/j.tibs.2014.07.007. Epub 2014 Aug 14. No abstract available.

PMID:
25131814
21.

Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells.

Yellen P, Foster DA.

Cancer Lett. 2014 Oct 28;353(2):258-63. doi: 10.1016/j.canlet.2014.07.027. Epub 2014 Jul 30.

22.

Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.

Saqcena M, Mukhopadhyay S, Hosny C, Alhamed A, Chatterjee A, Foster DA.

Oncogene. 2015 May 14;34(20):2672-80. doi: 10.1038/onc.2014.207. Epub 2014 Jul 14.

23.

Phospholipase D and the maintenance of phosphatidic acid levels for regulation of mammalian target of rapamycin (mTOR).

Foster DA, Salloum D, Menon D, Frias MA.

J Biol Chem. 2014 Aug 15;289(33):22583-8. doi: 10.1074/jbc.R114.566091. Epub 2014 Jul 2. Review.

24.

BxPC3 pancreatic cancer cells express a truncated Smad4 protein upon PI3K and mTOR inhibition.

Legendre O, Sookdeo A, Foster DA.

Oncol Lett. 2014 Apr;7(4):1165-1168. Epub 2014 Jan 28.

25.

Mutant ras elevates dependence on serum lipids and creates a synthetic lethality for rapamycin.

Salloum D, Mukhopadhyay S, Tung K, Polonetskaya A, Foster DA.

Mol Cancer Ther. 2014 Mar;13(3):733-41. doi: 10.1158/1535-7163.MCT-13-0762. Epub 2014 Jan 16.

26.

Metabolic vulnerability of KRAS-driven cancer cells.

Foster DA.

Mol Cell Oncol. 2014;1(3). pii: e963445. Epub 2014 Dec 23.

27.

Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle.

Saqcena M, Menon D, Patel D, Mukhopadhyay S, Chow V, Foster DA.

PLoS One. 2013 Aug 19;8(8):e74157. doi: 10.1371/journal.pone.0074157. eCollection 2013.

28.

Garcinia benzophenones inhibit the growth of human colon cancer cells and synergize with sulindac sulfide and turmeric.

Einbond LS, Mighty J, Kashiwazaki R, Figueroa M, Jalees F, Acuna UM, Le Gendre O, Foster DA, Kennelly EJ.

Anticancer Agents Med Chem. 2013 Dec;13(10):1540-50.

PMID:
23848206
29.

Phosphatidic acid and lipid-sensing by mTOR.

Foster DA.

Trends Endocrinol Metab. 2013 Jun;24(6):272-8. doi: 10.1016/j.tem.2013.02.003. Epub 2013 Mar 16.

30.

Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells.

Le Gendre O, Sookdeo A, Duliepre SA, Utter M, Frias M, Foster DA.

Mol Cancer Res. 2013 May;11(5):474-81. doi: 10.1158/1541-7786.MCR-12-0679. Epub 2013 Feb 26.

31.

Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-β-dependent G1 cell cycle arrest.

Yellen P, Chatterjee A, Preda A, Foster DA.

Cancer Lett. 2013 Jun 10;333(2):239-43. doi: 10.1016/j.canlet.2013.01.041. Epub 2013 Jan 29.

32.

Transition path times for nucleic Acid folding determined from energy-landscape analysis of single-molecule trajectories.

Neupane K, Ritchie DB, Yu H, Foster DA, Wang F, Woodside MT.

Phys Rev Lett. 2012 Aug 10;109(6):068102. Epub 2012 Aug 6.

PMID:
23006308
33.

Programmed -1 frameshifting efficiency correlates with RNA pseudoknot conformational plasticity, not resistance to mechanical unfolding.

Ritchie DB, Foster DA, Woodside MT.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16167-72. doi: 10.1073/pnas.1204114109. Epub 2012 Sep 17.

34.

High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.

Yellen P, Saqcena M, Salloum D, Feng J, Preda A, Xu L, Rodrik-Outmezguine V, Foster DA.

Cell Cycle. 2011 Nov 15;10(22):3948-56. doi: 10.4161/cc.10.22.18124. Epub 2011 Nov 15.

35.

Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s).

Foster DA, Yellen P, Xu L, Saqcena M.

Genes Cancer. 2010 Nov;1(11):1124-31. doi: 10.1177/1947601910392989.

36.

Single-molecule force spectroscopy of the add adenine riboswitch relates folding to regulatory mechanism.

Neupane K, Yu H, Foster DA, Wang F, Woodside MT.

Nucleic Acids Res. 2011 Sep 1;39(17):7677-87. doi: 10.1093/nar/gkr305. Epub 2011 Jun 8.

37.

Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1).

Xu L, Salloum D, Medlin PS, Saqcena M, Yellen P, Perrella B, Foster DA.

J Biol Chem. 2011 Jul 22;286(29):25477-86. doi: 10.1074/jbc.M111.249631. Epub 2011 May 28.

38.

Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells.

Toschi A, Lee E, Thompson S, Gadir N, Yellen P, Drain CM, Ohh M, Foster DA.

Cancer Lett. 2010 Dec 18;299(1):72-9. doi: 10.1016/j.canlet.2010.08.006.

39.

Phospholipase D stabilizes HDM2 through an mTORC2/SGK1 pathway.

Lyo D, Xu L, Foster DA.

Biochem Biophys Res Commun. 2010 May 28;396(2):562-5. doi: 10.1016/j.bbrc.2010.04.148. Epub 2010 May 8.

40.
41.

Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.

Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, Ohh M.

Cancer Res. 2009 Dec 1;69(23):9056-64. doi: 10.1158/0008-5472.CAN-09-1770. Epub 2009 Nov 17.

42.

The association between hospital outcomes and diagnostic imaging: early findings.

Lee DW, Foster DA.

J Am Coll Radiol. 2009 Nov;6(11):780-5. doi: 10.1016/j.jacr.2009.08.007.

PMID:
19878885
43.

Obituary: Hidesaburo Hanafusa (1929-2009).

Foster DA, Darnell JE Jr.

Nature. 2009 Apr 9;458(7239):718. doi: 10.1038/458718a. No abstract available.

PMID:
19360078
44.

Targeting mTOR with rapamycin: one dose does not fit all.

Foster DA, Toschi A.

Cell Cycle. 2009 Apr 1;8(7):1026-9. Epub 2009 Apr 2. Review.

45.

Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.

Foster DA.

Biochim Biophys Acta. 2009 Sep;1791(9):949-55. doi: 10.1016/j.bbalip.2009.02.009. Epub 2009 Mar 2. Review.

46.

Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.

Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA.

Mol Cell Biol. 2009 Mar;29(6):1411-20. doi: 10.1128/MCB.00782-08. Epub 2008 Dec 29.

47.

Low concentrations of a non-hydrolysable tetra-S-glycosylated porphyrin and low light induces apoptosis in human breast cancer cells via stress of the endoplasmic reticulum.

Thompson S, Chen X, Hui L, Toschi A, Foster DA, Drain CM.

Photochem Photobiol Sci. 2008 Nov;7(11):1415-21. doi: 10.1039/b806536e. Epub 2008 Aug 18.

48.

Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.

Toschi A, Lee E, Gadir N, Ohh M, Foster DA.

J Biol Chem. 2008 Dec 12;283(50):34495-9. doi: 10.1074/jbc.C800170200. Epub 2008 Oct 22.

49.

[Can defective TGF-Beta signaling be an Achilles heel in human cancer?].

Foster DA, Gadir N.

Ai Zheng. 2008 Aug;27(8):882-4. Review. Chinese.

PMID:
18710627
50.

Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells.

Garcia A, Zheng Y, Zhao C, Toschi A, Fan J, Shraibman N, Brown HA, Bar-Sagi D, Foster DA, Arbiser JL.

Clin Cancer Res. 2008 Jul 1;14(13):4267-74. doi: 10.1158/1078-0432.CCR-08-0102.

Supplemental Content

Loading ...
Support Center